
GlaxoSmithKline has decided not to sell off several of its ageing brands in the face of continuing business problems. The …

GlaxoSmithKline is looking to make more than £7 billion by selling off its ageing portfolio of established drugs. This is …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

